



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/652,864
				Filing Date	August 29, 2003
				First named Inventor	H. Kohler
				Group Art Unit	1641
				Examiner Name	n/a
Sheet	11	of	1	Attorney Docket Number	200-019

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Document		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code2			
/PKT/		5,800,991		Haley et al.	1998	
		6,238,667		Kohler	2001	
		2003/0103984		Kohler	06-05-2003	
		6,482,586		Arab et al.	11-19-2002	
		6,406,693		Thorpe et al.	06-18-2002	


FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office3	Number4	Kind Code5			

Examiner Signature	/Parithosh K Tungaturthi/	Date Considered	04/16/2007
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	10/652,864
		Filing Date	August 29, 2003
		First named Inventor	H. Kohler
		Group Art Unit	1641
		Examiner Name	P. Tungaturthi
Sheet 1	of 2	Attorney Docket Number	200-019

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
/PKT/		GHETIE, M., et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells," <u>PNAS USA</u> , (1997) 94: 7509-7514.	
		KANG, C-Y, et al. "Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide," <u>Science</u> , (1988) 240:1034-1036.	
		KANG, C-Y., et al., "Immunoglobulin with complementary paratope and idiotope," <u>J. Exp. Med.</u> (1986) 163: 787.	
		KAVERI, S., et al., "Antibodies of different specificities are self-binding: implication for antibody diversity," <u>Mol. Immunol.</u> , (1991) 2: 733-78.	
		KAVERI, S., et al., "Self-binding antibodies (autobodies) form specific complexes in solution," <u>J. Immunol.</u> (1990) 145: 2533-2538.	
		KOHLER, H., et al., "Superantibody activities: new players in innate and adaptive immune responses," <u>Immun. Today</u> , (1998) 19:221-227.	
		KOHLER, H., "Superantibodies: synergy of innate and acquired immunity," <u>Appl. Biochem. Biotechnol.</u> , (2000) 83: 1-9.	
		LIN, Y., et al., "Inhibition of nuclear translocation of transcription factor NF-kB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence," <u>J Biol Chem</u> , (1995) 270: 14255-14258.	
		MULLER, S., et al., "TransMabs: cell-penetrating antibodies, the next generation," <u>Expert Opin. Biol. Ther.</u> , (2005) 5: 237-241.	

Examiner Signature	/Parithosh K Tungaturthi/	Date Considered	04/16/2007
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <div style="text-align: center;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> </div>		<i>Complete if Known</i>	
		Application Number	10/652,864
		Filing Date	August 29, 2003
		First named Inventor	H. Kohler
		Group Art Unit	1641
		Examiner Name	P. Tungaturthi
		Attorney Docket Number	200-019
Sheet	2	of	2

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T8
/PKT/		ROJAS, M., et al., "Genetic engineering of proteins with cell membrane permeability," <u>Nat. Biotechnol.</u> , (1998) 16: 370-375.	
		ZHAO, Y., et al., "Chemical engineering of cell penetrating antibodies," <u>J. Immun. Methods</u> , (2001) 254: 137-145.	
		ZHAO, Y. et al., "Enhancing tumor targeting and apoptosis using noncovalent antibody homodimers," <u>J. Immunotherapy</u> , (2002) 25(5): 1-9.	
		ZHAO, Y., et al., "Enhanced Anti-B-cell Tumor Effects with Anti-CD20 Superantibody," <u>J. Immunotherapy</u> , (2002) 25: 57-62.	

Examiner Signature	/Parithosh K Tungaturthi/	Date Considered	04/16/2007
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.